Doug Galasko

5.1k total citations · 2 hit papers
23 papers, 2.5k citations indexed

About

Doug Galasko is a scholar working on Physiology, Psychiatry and Mental health and Molecular Biology. According to data from OpenAlex, Doug Galasko has authored 23 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Physiology, 11 papers in Psychiatry and Mental health and 3 papers in Molecular Biology. Recurrent topics in Doug Galasko's work include Alzheimer's disease research and treatments (10 papers), Dementia and Cognitive Impairment Research (10 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Doug Galasko is often cited by papers focused on Alzheimer's disease research and treatments (10 papers), Dementia and Cognitive Impairment Research (10 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Doug Galasko collaborates with scholars based in United States, Sweden and Switzerland. Doug Galasko's co-authors include Christopher Ernesto, Mary Sano, Steven H. Ferris, M Grundman, Ronald J. Thomas, David Bennett, Elaine K. Perry, Raj N. Kalaria, Zhenxin Zhang and Martin Prince and has published in prestigious journals such as Neurology, The Lancet Neurology and Cell stem cell.

In The Last Decade

Doug Galasko

23 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors

2008 890 citations Raj N. Kalaria, Gladys E. Maestre et al. The Lancet Neurology profile →
An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

1997 683 citations Doug Galasko, David Bennett et al. PubMed profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Doug Galasko United States	13	1.3k	989	408	300	273	23	2.5k
Edmond Teng United States	27	1.2k 0.9×	1.2k 1.2×	338 0.8×	296 1.0×	324 1.2×	80	2.6k
Deborah B. Marin United States	31	1.2k 0.9×	870 0.9×	258 0.6×	364 1.2×	190 0.7×	73	2.9k
Lena Kilander Sweden	31	1.4k 1.1×	1.3k 1.3×	560 1.4×	220 0.7×	361 1.3×	70	3.6k
Lisa J. Bain United States	29	1.1k 0.8×	1.2k 1.2×	578 1.4×	240 0.8×	514 1.9×	77	3.1k
Olivier Rouaud France	33	1.2k 0.9×	794 0.8×	432 1.1×	253 0.8×	360 1.3×	119	4.2k
Armin von Gunten Switzerland	32	1.3k 1.0×	879 0.9×	337 0.8×	260 0.9×	219 0.8×	229	3.3k
Ann Marie Hake United States	27	835 0.6×	738 0.7×	250 0.6×	242 0.8×	282 1.0×	68	2.3k
Peter Bentham United Kingdom	28	1.2k 0.9×	989 1.0×	380 0.9×	707 2.4×	326 1.2×	63	3.2k
David Ames Australia	26	1.6k 1.2×	1.0k 1.0×	287 0.7×	228 0.8×	278 1.0×	99	3.4k
Kathleen M. Hayden United States	36	1.6k 1.2×	1.6k 1.6×	571 1.4×	220 0.7×	469 1.7×	180	4.4k

Countries citing papers authored by Doug Galasko

Since Specialization

Citations

This map shows the geographic impact of Doug Galasko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Doug Galasko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Doug Galasko more than expected).

Fields of papers citing papers by Doug Galasko

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Doug Galasko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Doug Galasko. The network helps show where Doug Galasko may publish in the future.

Co-authorship network of co-authors of Doug Galasko

This figure shows the co-authorship network connecting the top 25 collaborators of Doug Galasko. A scholar is included among the top collaborators of Doug Galasko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Doug Galasko. Doug Galasko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Herdy, Joseph R., Larissa Traxler, Ravi Kant Agarwal, et al.. (2022). Increased post-mitotic senescence in aged human neurons is a pathological feature of Alzheimer’s disease. Cell stem cell. 29(12). 1637–1652.e6. 115 indexed citations

Goldman, Jennifer G., Bradley F. Boeve, Melissa J. Armstrong, et al.. (2021). Lewy Body Dementia Association’s Industry Advisory Council: proceedings of the second annual meeting. Alzheimer s Research & Therapy. 13(1). 111–122. 1 indexed citations

Dubois, Bruno, Nicolas Villain, Giovanni B. Frisoni, et al.. (2021). Recommendations of the International Working Group for the clinical diagnosis of Alzheimer’s disease. Alzheimer s & Dementia. 17(S5). 2 indexed citations

Reas, Emilie T., Denis S. Smirnov, Sarah J. Banks, Doug Galasko, & James B. Brewer. (2021). Brain microstructure mediates effects of tau on cognitive decline in early Alzheimer’s disease. Alzheimer s & Dementia. 17(S4). 1 indexed citations

Villain, Nicolas, Bruno Dubois, Giovanni B. Frisoni, et al.. (2021). Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group (IWG). Alzheimer s & Dementia. 17(S5). 4 indexed citations

Goldman, Jennifer G., Leah K. Forsberg, Bradley F. Boeve, et al.. (2020). Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials. Alzheimer s Research & Therapy. 12(1). 137–137. 34 indexed citations

Galasko, Doug, et al.. (2020). Longitudinal change in CSF biomarkers, especially NPTX2, in non‐demented elderly predicts cognitive decline and conversion to dementia. Alzheimer s & Dementia. 16(S5). 1 indexed citations

Jacobs, Diane M., David P. Salmon, Emily C. Edmonds, et al.. (2018). P1‐049: COMPOSITE ENDPOINTS FOR ALZHEIMER'S DISEASE CLINICAL TRIALS: IMPROVED PERFORMANCE VIA OPTIMAL WEIGHTING OF COMPONENT MEASURES. Alzheimer s & Dementia. 14(7S_Part_5). 1 indexed citations

Bekris, Lynn M., Gail Li, Doug Galasko, et al.. (2012). Tau phosphorylation pathway genes and cerebrospinal fluid tau levels in Alzheimer's disease. American Journal of Medical Genetics Part B Neuropsychiatric Genetics. 159B(7). 874–883. 14 indexed citations

10.

Galasko, Doug, et al.. (2009). Welcome to Alzheimer's Research & Therapy. Alzheimer s Research & Therapy. 1(1). 1–1. 13 indexed citations

11.

Wiltfang, Jens, Piotr Lewczuk, Peter Riederer, et al.. (2009). Trabalho de consenso de força-tarefa da WFSBP sobre marcadores biológicos das demências: contribuição da análise do LCR e do sangue para o diagnóstico precoce e diferencial das demências. Archives of Clinical Psychiatry (São Paulo). 36. 1–16. 2 indexed citations

12.

Kalaria, Raj N., Gladys E. Maestre, Raúl L. Arizaga, et al.. (2008). Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. The Lancet Neurology. 7(9). 812–826. 890 indexed citations breakdown →

13.

Harris‐White, Marni E., et al.. (2004). Role of LRP in TGFβ2‐mediated neuronal uptake of Aβ and effects on memory. Journal of Neuroscience Research. 77(2). 217–228. 21 indexed citations

14.

Teter, Bruce, et al.. (2002). Defective neuronal sprouting by human apolipoprotein E4 is a gain‐of‐negative function. Journal of Neuroscience Research. 68(3). 331–336. 64 indexed citations

15.

Teter, Bruce, et al.. (1999). Human Apolipoprotein E Isoform‐Specific Differences in Neuronal Sprouting in Organotypic Hippocampal Culture. Journal of Neurochemistry. 73(6). 2613–2616. 76 indexed citations

16.

Galasko, Doug, Christopher M. Clark, Lei Chang, et al.. (1997). Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology. 48(3). 632–635. 110 indexed citations

17.

Ferris, Steven H., Joan Mackell, Richard C. Mohs, et al.. (1997). A multicenter evaluation of new treatment efficacy instruments for Alzheimer's disease clinical trials: overview and general results. The Alzheimer's Disease Cooperative Study.. PubMed. 11 Suppl 2. S1–12. 39 indexed citations

18.

Galasko, Doug, David Bennett, Mary Sano, et al.. (1997). An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.. PubMed. 11 Suppl 2. S33–9. 683 indexed citations breakdown →

19.

Wiederholt, W. C., Doug Galasko, & David P. Salmon. (1997). 2-12-22 Utility of the CASI and IQCODE as screening instruments for dementia in natives of Guam. Journal of the Neurological Sciences. 150. S89–S89. 8 indexed citations

20.

Morris, John C., S. D. Edland, Christine Clark, et al.. (1993). The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Neurology. 43(12). 2457–2457. 364 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact